Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | QDPR | P09417 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666756 | 0.87 | PDE4B (0.40) | CYP1A2TDP1EPHX2EPHX1QDPR | |
| SCHEMBL6044667 | 0.87 | PDE4B (0.40) | CYP1A2TDP1EPHX2EPHX1QDPR | |
| SCHEMBL17642630 | 0.87 | PDE4B (0.40) | CYP1A2TDP1EPHX2EPHX1QDPR | |
| SCHEMBL25666700 | 0.84 | CXCR3 (0.46) | KDM4ESMN1; SMN2ALDH1A1POLB | |
| SCHEMBL23134531 | 0.84 | CYP1A2 (0.46) | CYP1A2TDP1EPHX2EPHX1QDPR | |
| SCHEMBL28107006 | 0.84 | NPC1 (0.42) | KDM4ESMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL14000542 | 0.83 | RAB9A (0.39) | KDM4ESMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL1935423 | 0.82 | RAB9A (0.41) | KDM4ESMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL23134532 | 0.82 | LMNA (0.40) | KMT2A | |
| SCHEMBL1422981 | 0.80 | KMT2A (0.40) | EPHX2KDM4ESMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145315-A1 | TARGETED PROTEIN DEGRADERS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | NORTHWESTERN UNIVERSITY (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024129948-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF S1P5 | CELGENE CORPORATION (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-11914248-B2 | Photo-alignment copolymer, photo-alignment film, and optical laminate | FUJIFILM CORPORATION (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024020458-A1 | METHOD OF TREATING ORGAN DISEASES OR DISORDERS WITH ASK1 INHIBITORS | Seal Rock Therapeutics, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4288426-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | Black Diamond Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023218187-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE | UNIVERSITY OF DUNDEE (GB) | 2023-11-16 | — | — | WO | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-23 | — | — | US | disclosed |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-23 | — | — | US | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-6265418-B1 | ANTICOAGULANTS | UBE INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1020467-A1 | N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF | UBE INDUSTRIES LIMITED (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | CYP1A2 4819/4885TDP1 1589/4885EPHX2 3297/4885 |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | REN, AVPR1B, WNK1 | CYP1A2 909/4885TDP1 4695/4885EPHX2 3316/4885 |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | CYP1A2 1848/4885TDP1 381/4885EPHX2 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.